^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iparomlimab (QL1604)

    i
    Other names: QL1604, PSB103, QL-1604, QL 1604
    Company:
    Qilu Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    4d
    CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer (clinicaltrials.gov)
    P2, N=106, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2 trial • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • BRAF V600
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    7d
    Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    A Phase II Clinical Study of Sequential Iparomlimab and Tuvonralimab Combined with Chemotherapy Following Local Radiotherapy in Breast Cancer Patients with Poor Response to Neoadjuvant Chemotherapy (ChiCTR2600117206)
    P=N/A, N=30, Not yet recruiting, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    Study on the efficacy and safety of QL1706 combined with Senaparib in neoadjuvant therapy for ovarian Cancer: A prospective, single-arm clinical study (ChiCTR2600116175)
    P=N/A, N=20, Not yet recruiting, The Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University
    New trial
    |
    Paishuning (senaparib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    A single-center, single-arm clinical study on the efficacy and safety of Iparomlimab and Tuvonralimab combined with chemotherapy as neoadjuvant therapy in patients with muscle-Invasive bladder cancer (MIBC) (ChiCTR2500115561)
    P=N/A, N=20, Not yet recruiting, Tianjin Cancer Hospital Airport Hospita; Tianjin Cancer Hospital Airport Hospita
    New trial
    |
    carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    Prospective, Open-Label, Single-Center Clinical Study of Iparomlimab and Tuvonralimab Combined with AG Regimen plus SBRT versus Epalolitovorimab Combined with AG Regimen as First-Line Treatment for Unresectable Locally Advanced or Metastatic Pancreatic Cancer (ChiCTR2500115120)
    P=N/A, N=40, Not yet recruiting, The First Affiliated Hospital of University of science and technology of China; The First Affiliated Hospital of University of science and technology
    New trial
    |
    gemcitabine • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    Iparomlimab and Tuvonralimab combined with chemotherapy as second-line treatment for locally advanced or metastatic pancreatic cancer A prospective, open-label, single-arm clinical study (ChiCTR2500114040)
    P=N/A, N=29, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital
    New trial
    |
    5-fluorouracil • irinotecan • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    An Exploratory Study of Iparomlimab/Tuvonralimab (QL1706) Combined with Induction Chemotherapy and Radio(chemo)therapy for the Full-course Treatment of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (ChiCTR2500113996)
    P=N/A, N=50, Not yet recruiting, Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    Real-world study of Iparomlimab/Tuvonralimab-based therapy for hepatobiliary tumors (ChiCTR2500113841)
    P=N/A, N=30, Not yet recruiting, Nantong Tumor Hospital; Nantong Tumor Hospital
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    Exploratory Clinical Study of TACE Combined with Iparomlimab and Tuvonralimab and Donafenib in Conversion Therapy for Unresectable Locally Advanced and Advanced Hepatocellular Carcinoma (ChiCTR2500112149)
    P=N/A, N=42, Not yet recruiting, The First Affiliated Hospital of University of science and technology of China; The First Affiliated Hospital of University of science and technology
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab) • Zepsun (donafenib) • iparomlimab (QL1604)
    8d
    A single-arm, multicenter study of Iparomlimab and Tuvonralimab in the treatment of patients with advanced esophageal squamous cell carcinoma who have progressed following immune checkpoint inhibitor (ChiCTR2500111383)
    P=N/A, N=56, Not yet recruiting, Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital
    New trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8d
    A prospective, observational, single arm clinical study to explore the efficacy and safety of concurrent chemoradiotherapy with cisplatin / carboplatin combined with Iparomlimab and Tuvonralimab in the adjuvant treatment of postoperative cervical cancer patients with high-risk factors (ChiCTR2500115098)
    P4, N=60, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New P4 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)